News | Breast Imaging | November 16, 2020

NorthShore University HealthSystem Adopts Groundbreaking densitas intelliMammo Artificial Intelligence Platform for Precision Breast Cancer Screening

DensitasInc., a leading provider of A.I. technologies for digital mammography and breast screening, announced that NorthShore University HealthSystem (NorthShore), will deploy the densitas  platform across its mammography facilities

November 16, 2020 — Densitas Inc., a leading provider of A.I. technologies for digital mammography and breast screening, announced that NorthShore University HealthSystem (NorthShore), will deploy the densitas  platform across its mammography facilities. With this deployment, breast density, clinical image quality, and breast cancer risk assessments will be automatically generated for every mammogram taken throughout the health system.

NorthShore is an award-winning integrated healthcare delivery system that has been consistently ranked as a Top 15 Teaching Hospital in the U.S. and is widely recognized as a leader in the implementation of innovative technologies. Headquartered in Evanston, Illinois, NorthShore includes four hospitals — Evanston, Glenbrook, Highland Park, and Skokie — .and a 900-physician multispecialty group practice, NorthShore Medical Group, with 130 locations in the Chicagoland area. NorthShore has established itself as a leader in medical informatics and advanced information technology. In 2003, the health system was among the first in the country to successfully implement a system wide EMR with demonstrable benefits in quality, safety, efficiency, and service delivery.

“Mammography is widely recognized as the best available frontline tool for early breast cancer detection and treatment, but its sensitivity can be affected by mammographic density and clinical image quality,”  said Georgia Spear, M.D., Chief of Breast Imaging at NorthShore, who was instrumental in getting Illinois’ breast density notification law passed. “Women should have access to personalized breast screening based on high quality imaging. The introduction of densitas intelliMammo to our mammography practice supports our commitment to provide our patients the best quality of care with the most innovative technologies available.”

“We are honored that Densitas’ solutions will be part of the strong NorthShore culture of innovation,” said Mo Abdolell, CEO of Densitas. “We are excited to have Dr. Spear, a leader in patient engagement and a passionate proponent of breast cancer screening, as a Clinical Advisor. NorthShore’s adoption of densitas intelliMammo marks a significant milestone in our US market expansion at a time when patient and process management is all the more challenging due to COVID-19. The overwhelming response has been that densitas intelliMammo represents a rare and disruptive innovation in screening mammography.”

densitas intelliMammo is a breakthrough A.I. platform, comprising densitas qualityai, densitasdensityai, and densitas riskai, that provides a comprehensive solution for patient and process management in screening mammography. densitas intelliMammo provides clinical image quality, breast density, and cancer risk assessments that are accessible on-demand at point-of-care by radiologists and radiological technologists, and through a web-based embedded analytics platform by diagnostic imaging managers, QC technologists, and health system administrators. The Densitas team is dedicated to making top in class A.I. solutions for breast cancer screening in the world, and to moving the needle for better patient care.

densitas® densityai generates automated and reliably reproducible breast density assessments from standard clinical use mammograms that align with the ACR BI-RADS 5th edition density classification scale.

densitas® qualityai produces automated and standardized clinical image quality assessment supporting compliance with the FDA MQSA EQUIP.

densitas® riskai provides automated rapid breast cancer risk assessment based on image-derived features; results are reliably reproducible and less prone to bias.

For more information: www.densitas.health

Related Content

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms.

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms. Images from Christiane Kuhl, M.D.

Feature | MRI Breast | March 04, 2021 | By Dave Fornell, Editor
Dense breast tissue can hide cancers i
CT imaging radiation dose tracking software from Imalogix displayed at RSNA 2019.

CT imaging radiation dose tracking software from Imalogix displayed at RSNA 2019. Photo by Dave Fornell.

Feature | Radiation Dose Management | March 04, 2021 | By Dave Fornell
More than a decade ago, there was an alarming, rapid rise in ionizing radiation exposure in the U.S.
GE Healthcare introduced its artificial intelligence (AI) automation features on its Voluson Swift ultrasound platform at the 2020 Radiological Society of North America (RSNA) virtual meeting. Features of this system include semi-automated contouring, auto identification of fetal anatomy and positioning on imaging. AI is seeing increasing integration in ultrasound systems from numerous vendors.

GE Healthcare introduced its artificial intelligence (AI) automation features on its Voluson Swift ultrasound platform at the 2020 Radiological Society of North America (RSNA) virtual meeting. Features of this system include semi-automated contouring, auto identification of fetal anatomy and positioning on imaging. AI is seeing increasing integration in ultrasound systems from numerous vendors.

Feature | Ultrasound Imaging | March 04, 2021 | By Dave Fornell, Editor
Recent advances in ultrasound image sy...
Philips and The Walt Disney Company EMEA announced they are teaming up to test the effects of custom-made animation, including specially-made Disney stories, within Philips Ambient Experience, a solution that integrates architecture, design and enabling technologies, such as dynamic lighting, video projections and sound, to allow patients and staff to personalize their environment to create a relaxing atmosphere

Study will explore the effects and use of animated stories and characters, including Disney favorites, as part of Philips Ambient Experience solution.

News | Magnetic Resonance Imaging (MRI) | March 03, 2021
March 3, 2021 — ...
Researchers said women who skip even one scheduled mammography screening before a breast cancer diagnosis face a significantly higher risk of dying from the cancer.

Getty Images

News | Mammography | March 03, 2021
March 3, 2021 — Attendance at regular ...
Guerbet announced the launch of OptiProtect 3S, a new range of technical services for its injection solutions. OptiProtect 3S is designed to support imaging centers in the daily use and protection of their injection solutions.
News | Contrast Media Injectors | February 25, 2021
February 25, 2021 — Guerbet announced the launch of ...
55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging